Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification of sunitinib (SU11248) and its active metabolite, N-desethyl sunitinib (SU12662), in human plasma: Application to an explorative study

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 879, Issue 11-12, 2011, Pages 695-706

  Rodamer, Michael ^a   Elsinghorst, Paul W ^b   Kinzig, Martina ^a   Gütschow, Michael ^b   Sörgel, Fritz ^a,c  

^a IBMP Institute for Biomedical and Pharmaceutical Research   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

LC MS MS analysis; N desethyl sunitinib; Sunitinib; Tandem mass spectrometry; Tyrosine kinase inhibitors

Indexed keywords

LC-MS/MS; N-DESETHYL SUNITINIB; SUNITINIB; TANDEM MASS SPECTROMETRY; TYROSINE KINASE INHIBITORS;

ACETONITRILE; AMINO ACIDS; CHROMATOGRAPHY; ENZYMES; LIQUIDS; MASS SPECTROMETRY; PLASMA (HUMAN); PLASMAS; SAMPLING;

PLASMA STABILITY;

DEETHYLSUNITINIB; DRUG METABOLITE; PROTEIN TYROSINE KINASE INHIBITOR; SU 12662; SUNITINIB; UNCLASSIFIED DRUG;

ACCURACY; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DRUG DETERMINATION; HUMAN; LIQUID CHROMATOGRAPHY; NEWBORN; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; STANDARD; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; INDOLES; INFANT, NEWBORN; LINEAR MODELS; MALE; PYRROLES; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 79952902010     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2011.02.006     Document Type: Article

References (29)

1. Izzedine H., Buhaescu I., Rixe O., Deray G. Cancer Chemother. Pharmacol. 2007, 60:357.
2. Atkins M., Jones C.A., Kirkpatrick P. Nat. Rev. Drug Discov. 2006, 5:279.
3. Grandinetti C.A., Goldspiel B.R. Pharmacotherapy 2007, 27:1125.
4. Papaetis G.S., Syrigos K.N. BioDrugs 2009, 23:377.
5. Faivre S., Demetri G., Sargent W., Raymond E. Nat. Rev. Drug Discov. 2007, 6:734.
6. Roskoski R. Biochem. Biophys. Res. Commun. 2007, 356:323.
7. Le Tourneau C., Raymond E., Faivre S. Ther. Clin. Risk Manag. 2007, 3:341.
8. Goodman V.L., Rock E.P., Dagher R., Ramchandani R.P., Abraham S., Gobburu J.V.S., Booth B.P., Verbois S.L., Morse D.E., Liang C.Y., Chidambaram N., Jiang J.X., Tang S., Mahjoob K., Justice R., Pazdur R. Clin. Cancer Res. 2007, 13:1367.
9. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J.O., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J.M. Clin. Cancer Res. 2003, 9:327.
10. Bello C.L., Sherman L., Zhou J., Verkh L., Smeraglia J., Mount J., Klamerus K.J. Anticancer Drugs 2006, 17:353.
11. Barattè S., Sarati S., Frigerio E., James C.A., Ye C., Zhang Q. J. Chromatogr. A 2004, 1024:87.
12. Haouala A., Zanolari B., Rochat B., Montemurro M., Zaman K., Duchosal M.A., Ris H.B., Leyvraz S., Widmer N., Decosterd L.A. J. Chromatogr. B 2009, 877:1982.
13. Minkin P., Zhao M., Chen Z., Ouwerkerk J., Gelderblom H., Baker S.D. J. Chromatogr. B 2008, 874:84.
14. Blanchet B., Saboureau C., Benichou A.S., Billemont B., Taieb F., Ropert S., Dauphin A., Goldwasser F., Tod M. Clin. Chim. Acta 2009, 404:134.
15. Etienne-Grimaldi M., Renée N., Izzedine H., Milano G. J. Chromatogr. B 2009, 877:3757.
16. Sun L., Tran N., Tang F., App H., Hirth P., McMahon G., Tang C. J. Med. Chem. 1998, 41:2588.
17. Zhou Q., Gallo J.M. J. Pharm. Biomed. Anal. 2010, 51:958.
18. D. Song, W. Wong, P. Giannousis, in: Proceedings of the AAPS Conference, November 2002.
19. Elsinghorst P.W., Gütschow M. J. Label. Compd. Radiopharm. 2009, 52:360.
20. U.S. Department of Health and Human Services, Food and Drug Administration, Guidance for industry: bioanalytical method validation, 2001.
21. European Medicines Agency, Committee for Medicinal Products for Human Use, Guideline on validation of bioanalytical methods, 2009.
22. Kroll M.H., Elin R.J. Clin. Chem. 1994, 40:1996.
23. Chin C., Zhang Z.P., Karnes H.T. J. Pharm. Biomed. Anal. 2004, 35:1149.
24. Rosenthal M.A., Katz H.B. Clin. Chim. Acta 2011, 412:665.
25. Lindauer A., Di Gion P., Kanefendt F., Tomalik-Scharte D., Kinzig M., Rodamer M., Dodos F., Sörgel F., Fuhr U., Jaehde U. Clin. Pharmacol. Ther. 2010, 87:601.
26. Honeywell R., Yarzadah K., Giovannetti E., Losekoot N., Smit E.F., Walraven M., Lind J.S.W., Tibaldi C., Verheul H.M., Peters G.J. J. Chromatogr. B 2010, 878:1059.
27. Britten C.D., Kabbinavar F., Hecht J.R., Bello C.L., Li J., Baum C., Slamon D. Cancer Chemother. Pharmacol. 2008, 61:515.
28. Fiedler W., Serve H., Döhner H., Schwittay M., Ottmann O.G., O'Farrell A., Bello C.L., Allred R., Manning W.C., Cherrington J.M., Louie S.G., Hong W., Brega N.M., Massimini G., Scigalla P., Berdel W.E., Hossfeld D.K. Blood 2005, 105:986.
29. de Bruijn P., Sleijfer S., Lam M., Mathijssen R.H.J., Wiemer E.A.C., Loos W.J. J. Pharm. Biomed. Anal. 2010, 51:934.